


Product Details

Product name:	Anti-cMet & EGFR (Amivantamab Biosimilar)	SKU:	BIO0014SM
Target Name:	cMet & EGFR	Size:	100ug/ 1mg/ 5mg
Target Uniprot:	P08581 & P00533	Concentration:	Lyophilized
Clone#:	Amivantamab (Bispecific)	Isotype:	IgG-like
Reactivity:	Human	Calculated M.W.:	145.9 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	100 mM Pro-Ac 20mM Arg pH 5.0	Conjugation:	None
Storage:	-20°C for 2 years under sterile conditions; -20°C for 1 year under sterile conditions; Avoid repeated freeze-thaw cycles.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH ₂ O	Purification:	Protein A


Data

Purity: SDS-PAGE




Anti-cMet & EGFR Reference Antibody (Amivantamab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity: SEC-HPLC




The purity of Anti-cMet & EGFR Reference Antibody (Amivantamab) is 98.79% , determined by SEC-HPLC.

ELISA



Amivantamab bound to ERBB1/EGFR/HER1 protein, and then rebounded to secondary antibodies(Anti-Human- κ + λ -HRP) , and read OD450. As shown in fig, Amivantamab bound human ERBB1/EGFR/HER1 Protein-Fc, and the EC₅₀ was 0.232 nM.


ELISA



Amivantamab bound to cMet protein, and then rebounded to secondary antibodies(Anti-Human-IgG-Fc-HRP) , and read OD450. As shown in fig, Amivantamab bound human cMet Protein-His, and the EC₅₀ was 0.004 nM.


Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

Bioactivity: FACS




Amivantamab bound to EGFR-CHO-K cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Amivantamab bound to EGFR-CHO-K cells, and the EC50 was 2.161 nM.

Bioactivity: FACS



Amivantamab bound to huMet-HEK293(A3) cells, and then rebounded to fluorescent secondary antibodies(Anti-Human IgG, Fcγ PE) , and test by flow cytometry. As shown in fig, Amivantamab bound to huMet-HEK293(A3) cells, and the EC50 was 0.609 nM.

Function: Luciferase



Co-incubation of Amivantamab with HGF, then with the addition of Human c-MET (Luc) HEK293 Reporter cells and incubated for 6 hoursBright-Lite was used to detect the fluorescent signal. As shown in fig, Amivantamab was able to block HGF/c-Met signaling pathway, and the IC50 was 0.166 nM.